Abstract
Colorectal cancer is a common malignancy in the United States and a significant cause of mortality yearly. Most recently, target-directed therapies have been added to the armamentarium. These include agents directed at the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). These agents improve survival in some patients; however, they are associated with high costs and increased toxicities. It is, therefore, necessary for a biomarker to be developed to enrich the patient population receiving these agents. Numerous potential biomarkers have been investigated including EGFR copy number, EGFR mutations, PTEN, AKT, KRAS, and the development of the acneiform rash. Here we review the data on KRAS mutation status and the response to treatment of patients with metastatic colorectal cancer (mCRC). These patients have received the EGFR-directed agents, cetuximab and panitumumab. In addition, a cost analysis is also performed to determine the cost effectiveness of KRAS mutation analysis.
Keywords: Cetuximab, panitumumab, EGFR, KRAS, colorectal cancer.
Current Cancer Therapy Reviews
Title:KRAS Mutation Analysis Prior to EGFR-Directed Therapy for Metastatic Colorectal Cancer: A Review and Cost Analysis
Volume: 6 Issue: 4
Author(s): Dustin Deming and Kyle Holen
Affiliation:
Keywords: Cetuximab, panitumumab, EGFR, KRAS, colorectal cancer.
Abstract: Colorectal cancer is a common malignancy in the United States and a significant cause of mortality yearly. Most recently, target-directed therapies have been added to the armamentarium. These include agents directed at the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). These agents improve survival in some patients; however, they are associated with high costs and increased toxicities. It is, therefore, necessary for a biomarker to be developed to enrich the patient population receiving these agents. Numerous potential biomarkers have been investigated including EGFR copy number, EGFR mutations, PTEN, AKT, KRAS, and the development of the acneiform rash. Here we review the data on KRAS mutation status and the response to treatment of patients with metastatic colorectal cancer (mCRC). These patients have received the EGFR-directed agents, cetuximab and panitumumab. In addition, a cost analysis is also performed to determine the cost effectiveness of KRAS mutation analysis.
Export Options
About this article
Cite this article as:
Deming Dustin and Holen Kyle, KRAS Mutation Analysis Prior to EGFR-Directed Therapy for Metastatic Colorectal Cancer: A Review and Cost Analysis, Current Cancer Therapy Reviews 2010; 6 (4) . https://dx.doi.org/10.2174/157339410793358101
DOI https://dx.doi.org/10.2174/157339410793358101 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antiproliferative Efficacy of Angiotensin II Receptor Blockers in Prostate Cancer
Current Cancer Drug Targets Current Status of Clinical Trials for Glioblastoma
Reviews on Recent Clinical Trials Possible Predictive Value of Maspin Expression in Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Drug Delivery Systems for Chemotherapeutics through Selected Polysaccharidic Vehicles
Current Organic Chemistry The Role of DNA Methylation in the Pathogenesis and Treatment of Cancer
Current Clinical Pharmacology Deaza Analogs of Folic Acid as Antitumor Agents
Current Pharmaceutical Design Selenium and Colon Cancer – From Chemoprevention to New Treatment Modality
Anti-Cancer Agents in Medicinal Chemistry Possible Role of DNA Methylation in the Induction of Systemic Lupus Erythematosus
Current Rheumatology Reviews Synergistic Two-Way Interactions of Dietary Polyphenols and Dietary Components on the Gut Microbial Composition: Is There a Positive, Negative, or Neutralizing Effect in the Prevention and Management of Metabolic Diseases?
Current Protein & Peptide Science Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020)
Current Medicinal Chemistry BELFAST Centenarians: A Case of Optimal Cardiovascular Risk?
Current Pharmaceutical Design Targeting RAS Signaling Pathways in Juvenile Myelomonocytic Leukemia
Current Drug Targets Mechanisms of Action of Imidazoacridinone and Triazoloacridinone Derivatives in View of their Biological Activity
Current Pharmaceutical Analysis Anti-Tumor Efficacy of Pyrvinium Pamoate Nanoliposomes in an Experimental Model of Melanoma
Anti-Cancer Agents in Medicinal Chemistry APE1/Ref-1Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1
Current Molecular Pharmacology Microenvironmental Regulation of Cancer Stem Cell Phenotypes
Current Stem Cell Research & Therapy Near-infrared Light Activatable Multimodal Gold Nanostructures Platform: An Emerging Paradigm for Cancer Therapy
Current Cancer Drug Targets Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Targeting Protein Kinase Inhibitors with Traditional Chinese Medicine
Current Drug Targets Dietary Fish Oil Reduces Colon Cancer Risk
Current Organic Chemistry